Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
In 2000 alone, 2.7 million people in the European Union were diagnosed for cancer, and another 1.3 million people lost their lives to these diseases. The European Commission forecasts that incidences of cancer could increase by 245 through to 20351.
STADA is dedicated to playing its part in the battle against cancer by making Specialty oncology treatments available to as many patients as possible.
STADA offers approved biosimilar treatments in Europe for several prevalent types of cancer, including breast cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC) ovarian cancer and renal cell cancers. In selected markets, STADA also offers a biosimilar used to treat neutropenia in cancer patients.